Lilly's settlement on Zyprexa with US states the largest ever
This article was originally published in Scrip
Executive Summary
Lillyhas agreed to pay $62 million to settle claims by 32 states that the company engaged in improper marketing of its antipsychotic, Zyprexa (olanzapine), including marketing for paediatric uses and for elderly dementia patients, both off-label uses. This is the largest multi-state settlement by a drug maker in a civil state consumer-protection case, according to Oregon's attorney general Hardy Myers.